Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bausch Health Companies (TSE:BHC)
TSX:BHC
RESEARCH TOOLSreports
Bausch Health Companies (BHC) Stock Price & Analysis
120 Followers
BHC Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$8.32 - C$15.43
Previous CloseC$9.7
Volume222.65K
Average Volume (3M)377.24K
Market Cap
C$3.56B
Enterprise ValueC$34.31B
Total Cash (Recent Filing)$947.00M
Total Debt (Recent Filing)$22.39B
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Aug 06, 2024EPS Estimate
C$1.21Last Dividend Ex-Date
Nov 10, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)-1.67
Shares Outstanding366,796,721
10 Day Avg. Volume354,925
30 Day Avg. Volume377,236
Standard Deviation0.16
R-Squared0.07
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)-0.13
Price to Sales (P/S)1.39
Price to Cash Flow (P/CF)1.60
P/FCF Ratio0.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.93
Enterprise Value/Gross Profit5.54
Enterprise Value/Ebitda28.93
Forecast
1Y Price Target
C$16.08Price Target Upside70.31% Upside
Rating ConsensusHold
Number of Analyst Covering5
Bausch Health Companies News
PremiumCompany Announcements
Bausch Health Defends XIFAXAN® Patent Again
PremiumCompany Announcements
Bausch Health Shareholders Approve Key Proposals
Bulls Say, Bears Say
Bulls Say
Legal RulingThe U.S. Court of Appeals for the Federal Circuit upheld the District Court's rulings around Xifaxan which means that Norwich's generic application is barred from approval until 2029.
Market ImpactBHC shares have traded 25% higher in the past 3 months leading into the appellate court decision.
Patent StrengtheningAdditional patents have been issued to BHC as of 2023, which could strengthen their case against the Amneal lawsuit.
Bears Say
Financial HealthCertainty around Xifaxan is critical to the financial health of BHC, and the current legal situation could jeopardize or delay BLCO share distribution.
Generic CompetitionKey factors contributing to that uncertainty include the possibility that Norwich or another generics manufacturer could file a new ANDA claiming only the IBS indication.
LitigationUncertainty persists as additional litigation with Amneal is already underway, and it is not impossible that Norwich tries again.
---
Options Prices
Currently, No data available
---
Ownership Overview
70.37% Insiders
7.24% Mutual Funds
4.59% Other Institutional Investors
17.79% Public Companies and
Individual Investors
BHC FAQ
What was Bausch Health Companies’s price range in the past 12 months?
Bausch Health Companies lowest stock price was C$8.32 and its highest was C$15.43 in the past 12 months.
What is Bausch Health Companies’s market cap?
Currently, no data Available
When is Bausch Health Companies’s upcoming earnings report date?
Bausch Health Companies’s upcoming earnings report date is Aug 06, 2024 which is in 33 days.
How were Bausch Health Companies’s earnings last quarter?
Bausch Health Companies released its earnings results on May 02, 2024. The company reported C$0.863 earnings per share for the quarter, missing the consensus estimate of C$0.932 by -C$0.069.
Is Bausch Health Companies overvalued?
According to Wall Street analysts Bausch Health Companies’s price is currently Undervalued.
Does Bausch Health Companies pay dividends?
Bausch Health Companies pays a Quarterly dividend of C$1.37 which represents an annual dividend yield of N/A. See more information on Bausch Health Companies dividends here
What is Bausch Health Companies’s EPS estimate?
Bausch Health Companies’s EPS estimate is C$1.21.
How many shares outstanding does Bausch Health Companies have?
Bausch Health Companies has 366,796,720 shares outstanding.
What happened to Bausch Health Companies’s price movement after its last earnings report?
Bausch Health Companies reported an EPS of C$0.863 in its last earnings report, missing expectations of C$0.932. Following the earnings report the stock price went down -8.146%.
Which hedge fund is a major shareholder of Bausch Health Companies?
Among the largest hedge funds holding Bausch Health Companies’s share is Carl Icahn C. It holds Bausch Health Companies’s shares valued at 368M.
---
Bausch Health Companies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
C$16.08 (70.31% Upside)
C$16.08 (70.31% Upside)
Blogger Sentiment
Bullish
TSE:BHC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 311.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.77%
Trailing 12-Months
Company Description
Bausch Health Companies
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets.
---
BHC Company Deck
---
BHC Earnings Call
Q1 2024
0:00 / 0:00
---
BHC Revenue Breakdown
44.64% Pharmaceuticals
22.80% Devices
20.52% OTC
10.96% Branded and Other Generics
1.07% Other
---
BHC Stock 12 Month Forecast
Average Price Target
C$16.08
▲(70.31% Upside)
Technical Analysis
Bausch Health Companies
―
Perrigo Company
―
Eli Lilly & Co
―
Pfizer
―
Teva Pharmaceutical
―
Best Analysts Covering BHC
1 Year
1 Year Success Rate
10/12 ratings generated profit
1 Year Average Return
+22.43%
reiterated a sell rating 4 months ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +22.43% per trade.
---